 Metabolic Clearance Rate
"Metabolic Clearance Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.
| Descriptor ID |
D008657
|
| MeSH Number(s) |
E01.370.225.843 E05.200.843 G03.490 G07.690.595 G07.690.725.513
|
| Concept/Terms |
Metabolic Clearance Rate- Metabolic Clearance Rate
- Clearance Rate, Metabolic
- Clearance Rates, Metabolic
- Metabolic Clearance Rates
- Rate, Metabolic Clearance
- Rates, Metabolic Clearance
|
Below are MeSH descriptors whose meaning is more general than "Metabolic Clearance Rate".
Below are MeSH descriptors whose meaning is more specific than "Metabolic Clearance Rate".
This graph shows the total number of publications written about "Metabolic Clearance Rate" by people in this website by year, and whether "Metabolic Clearance Rate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 2 | 2 | | 1990 | 0 | 4 | 4 | | 1991 | 1 | 1 | 2 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 3 | 3 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 5 | 5 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 4 | 4 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 5 | 5 | | 2003 | 0 | 3 | 3 | | 2004 | 0 | 14 | 14 | | 2005 | 0 | 5 | 5 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 3 | 3 | | 2008 | 0 | 6 | 6 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 4 | 4 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 11 | 11 | | 2013 | 0 | 7 | 7 | | 2014 | 1 | 1 | 2 | | 2015 | 1 | 2 | 3 | | 2016 | 1 | 2 | 3 | | 2018 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Metabolic Clearance Rate" by people in Profiles.
-
Manley PE, Trippett T, Smith AA, Macy ME, Leary SES, Boklan J, Cohen KJ, Goldman S, Kilburn LB, Dhall G, Devin J, Herzog CE, Partap S, Fauchet F, Badreddine E, Bernard JP, Chi SN. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 09; 65(9):e27217.
-
Seifert SM, Castillo-Mancilla JR, Erlandson K, Morrow M, Gandhi M, Kuncze K, Horng H, Zheng JH, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL. Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy. J Acquir Immune Defic Syndr. 2018 03 01; 77(3):295-298.
-
Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. J Acquir Immune Defic Syndr. 2018 02 01; 77(2):193-198.
-
Dalesio NM, Hendrix CW, McMichael DH, Thompson CB, Lee CK, Pho H, Arias RS, Lynn RR, Galinkin J, Yaster M, Brown RH, Schwartz AR. Effects of Obesity and Leptin Deficiency on Morphine Pharmacokinetics in a Mouse Model. Anesth Analg. 2016 12; 123(6):1611-1617.
-
Emoto C, Fukuda T, Mizuno T, Schniedewind B, Christians U, Adams DM, Vinks AA. Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol. 2016 08; 5(8):411-7.
-
Gist KM, Goldstein SL, Joy MS, Vinks AA. Milrinone Dosing Issues in Critically Ill Children With Kidney Injury: A Review. J Cardiovasc Pharmacol. 2016 Feb; 67(2):175-81.
-
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Feb; 22(2):307-315.
-
Achanta S, Sewell A, Ritchey JW, Broaddus K, Bourne DW, Clarke CR, Maxwell LK. Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs. J Vet Pharmacol Ther. 2016 Jun; 39(3):224-36.
-
Harskamp-van Ginkel MW, Hill KD, Becker KC, Becker K, Testoni D, Cohen-Wolkowiez M, Gonzalez D, Barrett JS, Benjamin DK, Siegel DA, Banks P, Watt KM. Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review. JAMA Pediatr. 2015 Jul; 169(7):678-85.
-
Getts DR, Kramer WG, Wiseman AC, Flechner SM. The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human aß T cell receptor antibody, in renal transplant patients. Clin Pharmacokinet. 2014 Jul; 53(7):649-57.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|